Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect By: News Direct April 05, 2023 at 13:18 PM EDT --News Direct--Xeris Biopharma chairman and CEO Paul Edick joins Proactive's Natalie Stoberman to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals for further XeriJect development.Edick says the agreement will see Xeris using its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements. Regeneron will have an option to commercially license the Xeris technology for such molecules and nominate additional molecules for reformulation and potential commercialization. Contact DetailsProactive Investors+1 347-449-0879na-editorial@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/xeris-biopharma-enters-research-collaboration-with-regeneron-pharmaceuticals-to-advance-xeriject-468188646 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect By: News Direct April 05, 2023 at 13:18 PM EDT --News Direct--Xeris Biopharma chairman and CEO Paul Edick joins Proactive's Natalie Stoberman to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals for further XeriJect development.Edick says the agreement will see Xeris using its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements. Regeneron will have an option to commercially license the Xeris technology for such molecules and nominate additional molecules for reformulation and potential commercialization. Contact DetailsProactive Investors+1 347-449-0879na-editorial@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/xeris-biopharma-enters-research-collaboration-with-regeneron-pharmaceuticals-to-advance-xeriject-468188646